Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA

Amenós, Aleix Cases; Montoya, Juan Pedro-Botet; Fuster, Vicente; Alonso, Vivencio Barrios; Sala, Xavier Pintó; Gimilio, Juan Francisco Ascaso; Núñez-Cortés, Jesús Millán; Cumplido, Adalberto Serrano

doi:10.1016/j.nefro.2016.07.002

Cited by 3 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARSCoV-2 is a single-stranded RNA beta-coronavirus that encodes an RNA-dependent RNA polymerase (RdRp) and proteases. Favipiravir, formerly known as T-705, is a prodrug of the purine nucleotide favipiravir ribofuranosyl-5′-triphosphate [3]. The active agent inhibits RNA polymerase, stopping viral replication [4].…”

Section: Introductionmentioning

confidence: 99%

"Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel)"

Herrera García

2023

BJSTR

View full text Add to dashboard Cite

Background and Objectives:The SARS COV2 pandemic in 2020 associated with severe pneumonia has been the most prevalent clinical entity in the morbidity and mortality of the disease. New antiviral treatments have been used under different emergency protocols with the aim of reducing the spread of the virus and reducing its lethality. Since 2013, favipiravir is an antiviral used to treat resistant influenza. Recently, multiple studies in Japan, Russia and China have demonstrated its effectiveness under the inhibitory mechanism of the viral RNA polymerase, effectively reducing the multiplication of the virus. The result of the expert panel using the Delphi method on the use of Favipiravir in patients with COVID 19 in Mexico is presented.Methods: Using the Delphi method and a panel of experts, a questionnaire was developed that included a block of questions regarding the benefit and non-benefit of the treatment of a patient with COVID 19 since diagnosis, identification of risk factors and comorbidities, as well as the ideal candidate. by consensus to receive the therapy, ARTICLE INFO

show abstract

Section: Introductionmentioning

confidence: 99%

"Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel)"

Herrera García

2023

BJSTR

View full text Add to dashboard Cite

show abstract

A Delphi Study to Prioritize Evidence-Based Strategies for Cardiovascular Disease Care in India

Singh

Joshi

Venkateshmurthy

et al. 2023

Glob Implement Res Appl

View full text Add to dashboard Cite

Providing quality cardiovascular disease (CVD) care in low resource setting requires understanding of priority and effective interventions. This study aimed to identify and prioritize evidence-based quality improvement strategies for CVD care in India using a modified two-round Delphi process in which, we asked 46 experts (clinicians, researchers, program implementers and policy makers) to rate 25 proven CVD care strategies grouped into: (1) patient support, (2) information communication technology (ICT) for health, (3) group problem solving, (4) training, and (5) multicomponent strategy on a scale of 1 (highest/best)—5 (lowest/worst) on priority, relative advantage, and feasibility. Subsequently, we convened an expert consensus panel of 32 members to deliberate and achieve consensus regarding the prioritized set of strategies for CVD care. The Delphi study found that group problem solving strategies achieved the best score for priority (1.80) but fared poorly on feasibility (2.88). Compared to others, multicomponent strategies were rated favorably across all domains (priority = 1.84, relative advantage = 1.94, and feasibility = 2.40). The ICT for health strategies achieved the worst scores for priority = 2.01, relative advantage = 2.31, and feasibility = 2.85. Training and patient support strategies scored moderately across all domains. The expert panel narrowed the selection of a multicomponent strategy consisting of (1) electronic health records with clinical decision-support system, (2) non-physician health worker facilitated care, (3) patient education materials, (4) text-message based reminders for healthy lifestyle, and (5) audit and feedback report for providers. Future research will evaluate the real-world feasibility and effectiveness of the multicomponent strategy in patients with CVD in a low- and middle-income country setting. Supplementary Information The online version contains supplementary material available at 10.1007/s43477-023-00087-2.

show abstract

Los consensos: Una reivindicación del acto médico

Perineau

2020

Acta Colombiana de Cuidado Intensivo

View full text Add to dashboard Cite

Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA

Cited by 3 publications

References 37 publications

"Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel)"

"Mexican Delphi Consensus to Use Favipiravir in Patients with COVID 19 (Expert Panel)"

A Delphi Study to Prioritize Evidence-Based Strategies for Cardiovascular Disease Care in India

Los consensos: Una reivindicación del acto médico

Contact Info

Product

Resources

About